O2W is a best-in-class Self-Microemulsifying Drug Delivery System (SMEDDS) that significantly enhances the solubility and bioavailability of cannabinoids.
Free of Polyethylene Glycols (PEGs), O2W improves the safety of cannabinoids by reducing the impact on the liver through enhanced lymphatic absorption.
Water-free Concentrate
Formulation Platform
High-potency, fast-acting
(immediate-release)
Microencapsulated Powder
Formulation Platform
Extra high-potency,
tunable-release
Semi-solid FormulationPlatform
High-potency, extended-release
Our breakthrough, proprietary product platforms can be customized to produce an unmatched variety of dosage forms with tunable release profiles.
O2W has an unprecedented onset of action, with the maximum concentration of CBD achieved at 20-30 min compared to unformulated CBD at 4-6 hours. This means that the effects will be felt in minutes, not hours.
O2W also demonstrated a substantial improvement of CBD bioavailability through a significant increase in area under curve (AUC) and Cmax, compared to control group.
O2W self-microemulsification under an electronic microscope.
Micellae is an innovative technology-based company founded on 15 years of research at University of Toronto.
We aim to provide the most advanced Drug Delivery System to produce the highest performing pharmaceutical and medical products.
Our experts will work with you every step of the way to find the best solution for your product.
108 College St, Suite W680
Toronto, ON M5G 0C5
CANADA
Tel: 1(866) 642-3552
E-mail: Info@micellae.com
Copyright © 2024 MICELLAE Delivery Systems Inc. All rights reserved.